Mark de BOER
Partner, Index Ventures
Mark de Boer has for the last 15 years worked for, managed and founded early stage biopharmaceutical companies in the field of innovative novel biopharmaceuticals. He graduated in Biochemistry and holds a PhD from the University of Amsterdam. His research career was in field of immuno-modulation and he has pioneered recombinant antibody technology. He teaches entrepreneurship in the Life Sciences at the Utrecht University in The Netherlands. Mark is a Venture Partner with Index Ventures and is board member of several Index portfolio companies.
Contribution to the panel discussion:
- compare US and EU biotech with respect to VC funding and management
- lack of experienced pre-clinical and clinical development management willing to work in ("risky") biotech envirnoment
- funding gap for EU biotech companies is for clinical phase II stage companies (plenty of early stage funding and public funding is only available for late stage companies with phase III or marketed products).